An effective NF-kappaB inhibitor might be a great pain drug

If so, then effective, safe inhibition of NF-kB could result in great benefits to humanity. How might that be achieved?

What’s surprising, or not, is that neither in the abstract nor in the full article are any of the useful NF-kB inhibitors found in nature mentioned. You would think the author would at least give a hat tip to resveratrol, or green tea, or beets, turmeric, chocolate, ginger…

NF-kB inhibitors are all around us.

The publication:

FASEB J. 2008 Oct;22(10):3432-42. Epub 2008 Jun 17.

The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?

Summary of the abstract (or you can read the entire publication free online)

Several studies indicate that the nuclear factor-kappa B (NF-kappaB) -activation cascade plays a crucial role not only in immune responses, inflammation, and apoptosis but also in the development and processing of pathological pain (neuropathic pain.)

Accordingly, a pharmacological intervention into this pathway may have antinociceptive (anti-pain) effects and could provide novel treatment strategies for pain and inflammation.

In this review we summarize the role of NF-kappaB in the nervous system, its impact on nociception (pain perception,) and several approaches that investigated the effects of various modulators.

The results indicate that NF-kappaB has an impact on nociceptive transmission and processing and that a number of substances that inhibit the NF-kappaB-activating cascade are capable of reducing the nociceptive response in different animal models.

Therefore, a modulation of specific participants in the NF-kappaB signal transduction might exert a useful approach for the development of new painkillers.


NF-kB is the Master Switch controlling not only inflammation, but pain as well

By selecting from among the most potent NF-kB inhibitors and then combining those in an effective delivery system, pain and inflammation can be effectively treated with very little risk of side effects.

Sorry, comments are closed for this post.